Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2005
08/18/2005WO2005074919A1 Diurea derivatives
08/18/2005WO2005074918A1 The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
08/18/2005WO2005074917A1 Methods for treatment of complications of diabetes
08/18/2005WO2005074916A1 Methods and compositions for the treatment of lipodystrophy
08/18/2005WO2005074915A1 Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
08/18/2005WO2005074914A1 Anthelmintic composition
08/18/2005WO2005074913A2 Compositions and methods for treating contracture
08/18/2005WO2005074912A2 Antiparasitic composition containing an organic amine salt of closantel
08/18/2005WO2005074911A1 Protein kinase c activator
08/18/2005WO2005074910A1 Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis
08/18/2005WO2005074909A1 Combination drug
08/18/2005WO2005074908A1 Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
08/18/2005WO2005074907A1 Gene expression controlling agent
08/18/2005WO2005074905A1 Therapeutic/preventive agent for osteoporosis containing as component isotaxiresinol derived from taxus yunnanensis
08/18/2005WO2005074902A1 Rectal composition
08/18/2005WO2005074901A2 New effector conjugates, process for their production and their pharmaceutical use
08/18/2005WO2005074900A2 NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
08/18/2005WO2005074899A2 New compositions containing quinoline compounds
08/18/2005WO2005074898A2 Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori
08/18/2005WO2005074897A2 Formulation auxiliary agents (aminopropanoic acid derivative) in cosmetic or dermatological preparations
08/18/2005WO2005074895A1 Extended release coated microtablets of venlafaxine hydrochloride
08/18/2005WO2005074893A1 Stable amorphous forms of montelukast sodium
08/18/2005WO2005074891A1 Microemulsion formulations comprising particular substance p antagonists
08/18/2005WO2005074889A1 Novel compositions of taxol derivatives and the process for the manufacture thereof
08/18/2005WO2005074887A2 Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof
08/18/2005WO2005074886A1 Otic detergent composition for animals, with edta and chlorexhidine
08/18/2005WO2005074885A1 Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method
08/18/2005WO2005074884A2 Sustained release pharmaceutical composition of indapamide
08/18/2005WO2005074882A2 Flat system for using in the oral cavity
08/18/2005WO2005074720A1 Use and composition of a powder of high melting fatty substance to induce a prolonged satiety feeling
08/18/2005WO2005074719A1 Nutritional composiition for improving skin condition and preventing skin diseases
08/18/2005WO2005074718A1 Pharmaceutical or dietary compositions based on short-chain fatty acids and complex sugars, for intestinal disorders
08/18/2005WO2005074708A1 Feed additive for laying hens and feed containing the additive
08/18/2005WO2005074642A2 Chemical compounds
08/18/2005WO2005074632A2 Methods and compositions for treating cancer
08/18/2005WO2005074599A2 Naphthalimide dosing by n-acetyl transferase genotyping
08/18/2005WO2005074536A2 Compositions and methods using proton pump inhibitors
08/18/2005WO2005074535A2 Cholinesterase inhibitors for spinal cord disorders
08/18/2005WO2005074513A2 N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integrase inhibitors
08/18/2005WO2005074460A2 Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
08/18/2005WO2005062992A3 Substituted melatonin derivatives, process for their preparation, and methods of use
08/18/2005WO2005062852A3 COMPOSITIONS CONTAINING d-TOCOPHEROL COMPOUND POLYBASIC ACID PARTIAL ESTERS
08/18/2005WO2005058890A3 Hydronopol derivatives as agonists on human orl1 receptors
08/18/2005WO2005058888A3 Oxazolidinone-quinolone hybrid antibiotics
08/18/2005WO2005058421A3 Use of a compound having two gold (i) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold (i) atoms for the treatment of cancer
08/18/2005WO2005056554A3 Azepinoindole derivatives as pharmaceutical agents
08/18/2005WO2005056000A3 Neuroactive substance and uses of one such substance
08/18/2005WO2005055943A3 Vinorelbine derivatives
08/18/2005WO2005055921A3 Compositions for treatment of ear disorders and methods of use thereof
08/18/2005WO2005054264A8 Glycomimetic antagonists for both e- and p-selectins
08/18/2005WO2005053697A3 Treatment of sexual disorders
08/18/2005WO2005053613A3 Combinations for the treatment of fungal infections
08/18/2005WO2005051350A3 Water dispersible tablet
08/18/2005WO2005046661A3 Use of nitric oxide donors for the treatment of drug addiction
08/18/2005WO2005046601A3 4-phenyl piperdine sulfonyl glycine transporter inhibitors
08/18/2005WO2005044240A3 Stable lansoprazole formulation
08/18/2005WO2005044230A3 Controlled release analgesic suspensions
08/18/2005WO2005040345A3 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
08/18/2005WO2005039485A3 Gsk-3 inhibitors and uses thereof
08/18/2005WO2005035003A3 Compositions and methods for increasing drug efficiency
08/18/2005WO2005032572A3 Means and methods for the recruitment and identification of stem cells
08/18/2005WO2005032513A3 Pantoprazole multiparticulate formulations
08/18/2005WO2005030794A3 Hemiasterlin derivatives and uses thereof
08/18/2005WO2005026741A3 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
08/18/2005WO2005026318A3 Methods and compositions for producing antigenic responses
08/18/2005WO2005023830A3 Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular diseases
08/18/2005WO2005013909A3 Novel cathepsin k inhibitors
08/18/2005WO2005007868A3 Controlled platelet activation to monitor therapy of adp antagonists
08/18/2005WO2005007665A3 Lincomycin derivatives possessing antibacterial activity
08/18/2005WO2005004799A3 β-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF
08/18/2005WO2005000268A3 Bioerodible sustained release drug delivery systems
08/18/2005WO2004110387A3 Sigma ligands for neuronal regeneration and functional recovery
08/18/2005WO2004100931A3 Use of soaps such as magnesium stearate for increasing the release of drugs
08/18/2005WO2004100873A3 Compounds, compositions, and methods
08/18/2005WO2004098517A8 Methods of hormonal treatment utilizing extended cycle contraceptive regimens
08/18/2005WO2004091527A3 Delivery systems of homogeneous thermoreversible low viscosity polymannan gum films
08/18/2005WO2004075857A3 Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
08/18/2005WO2004045552A3 Compositions for treating and/or preventing diseases characterized by the presence of metal ions
08/18/2005WO2002099049A3 Tbc1d1s as modifiers of the p53 pathway and methods of use
08/18/2005US20050183146 Inhibitors of the inositol polyphosphate 5-phosphatase SHIP2 molecule
08/18/2005US20050182485 Local vascular delivery of cladribine in combination with rapamycin to prevent restenosis following vascular injury
08/18/2005US20050182463 Polymer compositions and methods for their use
08/18/2005US20050182418 Devices and methods for the restoration of a spinal disc
08/18/2005US20050182276 Process for the synthesis and crystalline form of agomelatine
08/18/2005US20050182256 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; antiproliferative
08/18/2005US20050182236 Star polymer such as of a polylactone based on a central phosphorus atom derived from phosphorus oxychloride (POCl3) or ethyl dichlorophosphate; biodegradable and/or biocompatible; sustained release drug delivery; reverse thermal gelation
08/18/2005US20050182143 Method for enhancing the bioavailability of ospemifene
08/18/2005US20050182142 1,2-alkanediol, and citral, geraniol, nerol, perillaldehyde, alpha -terpineol, dodecanol and/or L-carvone
08/18/2005US20050182141 drug abuse, drug addiction; reduce cravings for food or addictive substance such as cocaine, amphetamine, nicotine, opiates, tobacco, alcohol or ecstasy; ketone or hydroxy aryl-cycloalkyl sulfides or S-oxides thereof e.g. 1-(1-(3,4-dichlorophenyl)cyclobutyl)-2-(2-(dimethylamino)ethylthio)ethanone
08/18/2005US20050182140 Antimicrobial compositions
08/18/2005US20050182136 Side effect reduction
08/18/2005US20050182135 Enhancement of alcohol metabolism
08/18/2005US20050182134 Anticancer agents; phenyl amide or phenyl ester derivatives of flurbiprofen for example; prodrug of a quinone methide or iminoquinone methide
08/18/2005US20050182132 Androgen receptor modulators
08/18/2005US20050182131 1-Phenyl-2-dimethylaminomethyl cyclohexane compounds and therapies for depressive symptoms, pain and incontinence
08/18/2005US20050182130 Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics
08/18/2005US20050182129 Hair growth tonic
08/18/2005US20050182128 For preventing or reducing dysplastic lesions
08/18/2005US20050182127 Broad activity spectrum against both endo- and ectoparasites in and on warm-blooded animals and plants; antihelmintics; nematocides
08/18/2005US20050182126 2-Thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
1 ... 4573 4574 4575 4576 4577 4578 4579 4580 4581 4582 4583 4584 4585 4586 4587 4588 4589 4590 4591 4592 4593 ... 7860